대한의생명과학회지 (Biomedical Science Letters)

  • 제20권4호
  • /
  • Pages.227-236
  • /
  • 2014
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Gingko biloba Extract Ameliorates Colonic Inflammation in DSS-induced Model of Colitis in Mice

  • Rhee, Ki-Jong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Gwon, Sun-Yeong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Hwang, Soonjae (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Lee, Chang Gun (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University) ;
  • Jang, In-Ho (Department of Biomedical Laboratory Science, College of Health Sciences, Sangji University) ;
  • Wie, Myung-Bok (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University) ;
  • Jung, Bae Dong (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University)
  • 투고 : 2014.11.24
  • 심사 : 2014.12.22
  • 발행 : 2014.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ulcerative colitis (UC) is a serious gastrointestinal tract disease characterized by recurrent chronic inflammation and mucosal damage of the gastrointestinal tract. The conventional therapies of choice are anti-inflammatory agents, steroids and anti-TNF-${\alpha}$ therapy. However, inherent limitations in these therapies have steered many UC patients to supplement existing therapies with alternative medicinal products. In the current study, we tested the efficacy of Gingko bilola extract (EGb 761) in abating colonic inflammation in a DSS-induced murine model of colitis. C57BL/6 mice were administered 2% DSS in the drinking water for 7 days, then regular water for 7 days, and then 2% DSS for an additional 7 days. EGb 761 (1 mg/dose) was oral gavaged daily for the duration of the experiment. At the termination of the experiment, mice treated with EGb+DSS showed higher body weight, lower spleen weight and longer colon length compared to mice treated with DSS alone. HE-stained colon tissues also exhibited less histologic inflammation in mice treated with EGb+DSS mice compared to mice treated with DSS alone. The serum levels inflammatory cytokines, KC and TNF-${\alpha}$, were also decreased in mice treated with EGb+DSS compared to mice treated with DSS alone. Finally, addition of EGb 761 to TNF-${\alpha}$ treated colonic cell line (HT29/c1) decreased secretion of IL-8 in vitro. These results collectively suggest that EGb 761 abates induction of colitis in DSS-induced model of colitis in mice.

키워드

참고문헌

  1. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006. 55: 342-347. https://doi.org/10.1136/gut.2005.065557
  2. Cheng SM, Yang SP, Ho LJ, Tsao TP, Juan TY, Chang DM, Chang SY, Lai JH. Down-regulation of c-jun N-terminal kinaseactivator protein-1 signaling pathway by Ginkgo biloba extract in human peripheral blood T cells. Biochem Pharmacol. 2003. 66: 679-689. https://doi.org/10.1016/S0006-2952(03)00388-5
  3. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000. 1: 25-58. https://doi.org/10.2174/1389450003349380
  4. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des. 2004. 10: 261-264. https://doi.org/10.2174/1381612043386437
  5. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006. 12 Suppl 1: S3-9.
  6. Harputluoglu MM, Demirel U, Yucel N, Karadag N, Temel I, Firat S, Ara C, Aladag M, Karincaoglu M, Hilmioglu F. The effects of Gingko biloba extract on acetic acid-induced colitis in rats. Turk J Gastroenterol. 2006. 17: 177-182.
  7. Head K, Jurenka JS. Inflammatory bowel disease. Part II: Crohn's disease--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2004. 9: 360-401.
  8. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003. 98: 1563-1568. https://doi.org/10.1111/j.1572-0241.2003.07519.x
  9. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006. 203: 2473-2483. https://doi.org/10.1084/jem.20061099
  10. Koltermann A, Hartkorn A, Koch E, Furst R, Vollmar AM, Zahler S. Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 2007. 64: 1715-1722. https://doi.org/10.1007/s00018-007-7085-z
  11. Kotakadi VS, Jin Y, Hofseth AB, Ying L, Cui X, Volate S, Chumanevich A, Wood PA, Price RL, McNeal A, Singh UP, Singh NP, Nagarkatti M, Nagarkatti PS, Matesic LE, Auclair K, Wargovich MJ, Hofseth LJ. Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis. Carcinogenesis. 2008. 29: 1799-1806. https://doi.org/10.1093/carcin/bgn143
  12. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001. 159: 2001-2009. https://doi.org/10.1016/S0002-9440(10)63051-9
  13. Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 2002. 67: 235-257. https://doi.org/10.1016/S0301-0082(02)00015-1
  14. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci. 2008. 73: R14-19.
  15. Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther. 2013. 38: 77-97. https://doi.org/10.1111/apt.12345
  16. Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, Xavier RJ, Terhorst C, Podolsky DK, Bhan AK. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 2002. 122: 134-144. https://doi.org/10.1053/gast.2002.30347
  17. Mohanta TK, Tamboli Y, Zubaidha PK. Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod Res. 2014. 28: 746-752. https://doi.org/10.1080/14786419.2013.879303
  18. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989. 96: 795-803.
  19. Motawi TK, Rizk SM, Shehata AH. Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease. J Physiol Biochem. 2012. 68: 529-539. https://doi.org/10.1007/s13105-012-0168-9
  20. Mudter J, Amoussina L, Schenk M, Yu J, Brustle A, Weigmann B, Atreya R, Wirtz S, Becker C, Hoffman A, Atreya I, Biesterfeld S, Galle PR, Lehr HA, Rose-John S, Mueller C, Lohoff M, Neurath MF. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest. 2008. 118: 2415-2426.
  21. Mustafa A, El-Medany A, Hagar HH, El-Medany G. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res. 2006. 53: 324-330. https://doi.org/10.1016/j.phrs.2005.12.010
  22. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol. 2000. 19: 51-62. https://doi.org/10.3109/08830180009048389
  23. Neurath MF, Finotto S. Translating inflammatory bowel disease research into clinical medicine. Immunity. 2009. 31: 357-361. https://doi.org/10.1016/j.immuni.2009.08.016
  24. O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010. 16: 1411-1420. https://doi.org/10.1002/ibd.21217
  25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990. 98: 694-702.
  26. Oyama Y, Chikahisa L, Ueha T, Kanemaru K, Noda K. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res. 1996. 712: 349-352. https://doi.org/10.1016/0006-8993(95)01440-3
  27. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med. 2007. 58: 433-444. https://doi.org/10.1146/annurev.med.58.121205.100607
  28. Rhee K-J, Kim H-C, Jung BD. Effect of Ginkgo biloba extract on the survival rate in lipopolysaccharide-induced sepsis model mice. Korean J Vet Serv. 2012. 35: 191-195. https://doi.org/10.7853/kjvs.2012.35.3.191
  29. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998. 22: 382-389. https://doi.org/10.1007/s002689900401
  30. Sandberg-Gertzen H. An open trial of Cedemin, a Gingko biloba extract with PAF-antagonistic effects for ulcerative colitis. Am J Gastroenterol. 1993. 88: 615-616.
  31. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007. 42: 16-25.
  32. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010. 16: 1808-1813. https://doi.org/10.1002/ibd.21248
  33. Saxena A, Kaur K, Hegde S, Kalekhan FM, Baliga MS, Fayad R. Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitis. J Tradit Complement Med. 2014. 4: 203-217. https://doi.org/10.4103/2225-4110.139111
  34. Schuerer-Maly CC, Eckmann L, Kagnoff MF, Falco MT, Maly FE. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994. 81: 85-91.
  35. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, Richter J, Bojarski C, Schumann M, Fromm M. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009. 1165: 294-300. https://doi.org/10.1111/j.1749-6632.2009.04062.x
  36. Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jurgens M, Schmechel S, Konrad A, Goke B, Ochsenkuhn T, Muller-Myhsok B, Lohse P, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis. 2008. 14: 437-445. https://doi.org/10.1002/ibd.20339
  37. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci. 2002. 47: 1266-1278. https://doi.org/10.1023/A:1015362228659
  38. Silberstein RB, Pipingas A, Song J, Camfield DA, Nathan PJ, Stough C. Examining brain-cognition effects of ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task. Evid Based Complement Alternat Med. 2011. 2011: 164139.
  39. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007. 117: 514-521. https://doi.org/10.1172/JCI30587
  40. van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A. 2009. 1216: 2002-2032. https://doi.org/10.1016/j.chroma.2009.01.013
  41. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006. 116: 1310-1316. https://doi.org/10.1172/JCI21404
  42. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, An P, Liu SQ, Yu HG. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-$\alpha$, NF-kBp65, IL-6) in TNBSinduced colitis in rats. Mediators Inflamm. 2006. 2006: 92642.
  43. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzhelmer's disease. Cell Mol Biol (Noisy-le-grand). 2002. 48: 613-623.